Research

OCT-Angiography

Biomarkers in Ophthalmic Imaging

Artificial Intelligence

OCT-Angiography

First introduced in 1991, Optical Coherence Tomography (OCT) marks one of the biggest advances in ophthalmic imaging, which came out of a collaboration between MIT, Mass Eye and Ear, and MGH. We are studying how state-of-the-art wide-field Swpet Source OCT-Angiography (OCT-A) help us diagnose and prognosis of ocular and systemic diseases, such as diabetic retinoapthy and age-related macular degeneration. The Harvard Retinal Imaging Lab is equipped with the newest Swept Source OCT and Spectral Domain OCT with the most up to date technologies.

Biomarkers in Ophthalmic Imaging

Early detection is often critical to treatment of diseases. We are identifying novel biomarkers for patients with various retinal and choroidal disorders such as diabetic retinopathy and age-related macular degeneration to allow early detection. We are also looking at ophthalmic biomarkers for systemic diseases, such as Alzheimer’s disease, schizophrenia, COVID-19, and other systemic diseases. We have access to multiple Swept Source OCT devices, wide-field OCT-Angiography capability, ultrawide-field fundus photography, and utilize mulltitude of SD OCT and OCT-Angiography devices.

Artificial Intelligence

Artificial intelligence (AI) is changing healthcare. We are studying how we can apply AI and deep learning algorithms to retinal imaging and functional testing to help us with diagnosis and prognosis of various eye diseases such as diabetic retinopathy.

CONTACT

LOCATION

Main Campus: 243 Charles Street, Boston, MA 02114

Longwood Campus:  800 Huntington Avenue, Boston, MA  02115